Analysis of three-dimensional echo decorrelation and integrated backscatter imaging during ex vivo radiofrequency ablation

2020 ◽  
Vol 148 (4) ◽  
pp. 2558-2558
Author(s):  
Elmira Ghahramani Z. ◽  
Peter D. Grimm ◽  
E. G. Sunethra Dayavansha ◽  
Kathryn Eary ◽  
Michael Swearengen ◽  
...  
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Pranav Lanka ◽  
Kalloor Joseph Francis ◽  
Hindrik Kruit ◽  
Andrea Farina ◽  
Rinaldo Cubeddu ◽  
...  

AbstractAccurate monitoring of treatment is crucial in minimally-invasive radiofrequency ablation in oncology and cardiovascular disease. We investigated alterations in optical properties of ex-vivo bovine tissues of the liver, heart, muscle, and brain, undergoing the treatment. Time-domain diffuse optical spectroscopy was used, which enabled us to disentangle and quantify absorption and reduced scattering spectra. In addition to the well-known global (1) decrease in absorption, and (2) increase in reduced scattering, we uncovered new features based on sensitive detection of spectral changes. These absorption spectrum features are: (3) emergence of a peak around 840 nm, (4) redshift of the 760 nm deoxyhemoglobin peak, and (5) blueshift of the 970 nm water peak. Treatment temperatures above 100 °C led to (6) increased absorption at shorter wavelengths, and (7) further decrease in reduced scattering. This optical behavior provides new insights into tissue response to thermal treatment and sets the stage for optical monitoring of radiofrequency ablation.


2021 ◽  
pp. 101564
Author(s):  
Mohamed Hisham Aref ◽  
Ibrahim H. Aboughaleb ◽  
Abou-Bakr M. Youssef ◽  
Yasser H. El-Sharkawy

2014 ◽  
Author(s):  
Daniele Tosi ◽  
Edoardo Gino Macchi ◽  
Giovanni Braschi ◽  
Mario Gallati ◽  
Alfredo Cigada ◽  
...  

Radiology ◽  
2021 ◽  
pp. 203967
Author(s):  
Wen-Juan Lv ◽  
Xin-Yan Zhao ◽  
Dou-Dou Hu ◽  
Xiao-Hong Xin ◽  
Li-Li Qin ◽  
...  

2021 ◽  
Vol 13 ◽  
pp. 175883592110598
Author(s):  
Inken Flörkemeier ◽  
Tamara N. Steinhauer ◽  
Nina Hedemann ◽  
Magnus Ölander ◽  
Per Artursson ◽  
...  

Background: Ovarian cancer (OvCa) constitutes a rare and highly aggressive malignancy and is one of the most lethal of all gynaecologic neoplasms. Due to chemotherapy resistance and treatment limitations because of side effects, OvCa is still not sufficiently treatable. Hence, new drugs for OvCa therapy such as P8-D6 with promising antitumour properties have a high clinical need. The benzo[ c]phenanthridine P8-D6 is an effective inductor of apoptosis by acting as a dual topoisomerase I/II inhibitor. Methods: In the present study, the effectiveness of P8-D6 on OvCa was investigated in vitro. In various OvCa cell lines and ex vivo primary cells, the apoptosis induction compared with standard therapeutic agents was determined in two-dimensional monolayers. Expanded by three-dimensional and co-culture, the P8-D6 treated cells were examined for changes in cytotoxicity, apoptosis rate and membrane integrity via scanning electron microscopy (SEM). Likewise, the effects of P8-D6 on non-cancer human ovarian surface epithelial cells and primary human hepatocytes were determined. Results: This study shows a significant P8-D6-induced increase in apoptosis and cytotoxicity in OvCa cells which surpasses the efficacy of well-established drugs like cisplatin or the topoisomerase inhibitors etoposide and topotecan. Non-cancer cells were affected only slightly by P8-D6. Moreover, no hepatotoxic effect in in vitro studies was detected. Conclusion: P8-D6 is a strong and rapid inductor of apoptosis and might be a novel treatment option for OvCa therapy.


Sign in / Sign up

Export Citation Format

Share Document